Progentos Therapeutics said it received $65 million in funding to support the development of myelin regeneration medications able to restore function in people with multiple sclerosis (MS) and other diseases marked by myelin loss.
The biotech company said it will use the funds to advance its MS program to proof-of-concept clinical studies and expand its myelin-restoring small molecule pipeline to other degenerative conditions.
“While there are many treatments that are highly effective at slowing the progression of disease, there is a significant unmet need for new approaches that can regenerate myelin and restore function for patients with MS,” Chris Loose, PhD, Progentos’ CEO, said in a company press release. Loose founded the company along with Sanjay Magavi, PhD, chief scientific officer….read full story by clicking HERE.